SOCS-based strategies to impair pathological JAK/STAT activity were already reported for the treatment of cardiovascular diseases confirming the anti-inflammatory and atheroprotective properties of the SOCS1/SOCS3 gene delivery in experimental atherosclerosis models [25,26]. Here, SOCS3 is linked to cardiovascular disorder.